Business Wire

Fashion Concept GmbH: Jeremy Meeks to conquer fashion world

27.9.2019 14:25:00 EEST | Business Wire | Press release

Share

We are experiencing a time of social and technological revolution. Fashion Concept GmbH is not just a pioneer, it has also been able to sign a deal with one of the icons of the fashion industry, former "hot felon" Jeremy Meeks. Fashion Concept GmbH focuses on the international trade in textiles. By using sustainable materials and promoting investment in new technologies, the company aims to ensure the long-term availability of environmentally-friendly fashion.

The company's goal is to set new standards for sustainability. To reinforce this goal, Fashion Concept has just signed a $15 million deal with Jeremy Meeks to develop his own brand. For Meeks, who has been a regular presence on the catwalk for various fashion designers, this collaboration means a higher profile and a wider audience, because not only will he be a top model, but he will also be marketing his own fashion label.

It is not just this mega deal that is a milestone in Jeremy's career; his private life is also on the upswing. He was recently photographed with a well-known actress. But things are not just on the upswing for Jeremy: Fashion Concept GmbH, with its focus on uniquely innovative and sustainable technologies, is making a bold move with this deal as it seeks to drive forward change in the fashion industry. Fashion Concept aims to expand the growth in fashion and lifestyle brands. Higher revenues are being generated each year on Germany's fashion market, in retail and, in particular, through online business; private investors, too, will soon have the opportunity to benefit from this growth. The profit margins of often up to 30% will be of particular interest for investors.

This is precisely the market segment where Fashion Concept is active. In international trade, the company has seen a growth of almost 300% in its sales over the last two years alone. The company is already making profits in purchasing, since it can access its own production facilities in Turkey. In addition, merchandise such as textiles and accessories from many top manufacturers are being produced and purchased at very favourable conditions. The opportunity to purchase at high volumes allows savings of up to 90% to be achieved.

The company plans to purchase further top textile brands in 2020. This will not only expand its product offerings significantly, it will also have a direct impact on prices.

The group works with numerous distributors, allowing it to be able to choose the most efficient marketing channel for its products at all times. In this way, it can maximise the revenue from the quick sale of its merchandise.

The company does not rely on bank loans, but instead uses subordinated loans, bonds, profit participation rights, and silent partnerships for individuals who can directly benefit from the company's growth with a fixed return, currently at three to five percent.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Name:Oguzhan Dertli
Tel: 00905392010251
Email:ahmet@fashion-concept.com

Fashion Invest AG
De-Saint-Exupéry-Straße 10
60549 Frankfurt am Main
Tel.: +4969348713577

Email: press@fashion-invest.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye